# EDGAR Filing Document

**Accession Number:** 0001721484
**File Stem:** 0001213900-23-019022
**Filing Date:** 2023-3
**Character Count:** 20720
**Document Hash:** c9095bae1440994a010616d6b74d7753
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-019022.hdr.sgml**: 20230310

**ACCESSION NUMBER**: 0001213900-23-019022

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230310

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230310

**DATE AS OF CHANGE**: 20230310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Longeveron Inc.
- **CENTRAL INDEX KEY:** 0001721484
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 472174146
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40060
- **FILM NUMBER:** 23721963

**BUSINESS ADDRESS:**
- **STREET 1:** 1951 NW 7TH AVENUE
- **STREET 2:** SUITE 520
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33136
- **BUSINESS PHONE:** 305-302-7158

**MAIL ADDRESS:**
- **STREET 1:** 1951 NW 7TH AVENUE
- **STREET 2:** SUITE 520
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33136

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LONGEVERON LLC
- **DATE OF NAME CHANGE:** 20171101

?xml version="1.0" encoding="utf-8"?

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 8-K**

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): <u>March 10, 2023</u>

Commission File No**. 001-40060**

**Longeveron Inc.**

(Exact name of small business issuer as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **47-2174146** |
| (State or other jurisdiction of<br> incorporation or organization) | (I.R.S. Employer<br> Identification Number) |
| **1951 NW 7<sup>th</sup> Avenue** **, Suite 520**<br> **Miami, Florida** | **33136** |
| (Address of principal executive offices) | (Zip Code) |

---

---

| |
|:---|
| **(305) 909-0840** |
| (Issuer's telephone number, including area code) |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange<br> on which registered |
| **Class A Common Stock, par value $.001 per share** | **LGVN** | **The Nasdaq Capital Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 2.02. Results of Operations and Financial Condition**

On March 10, 2023, the Company announced financial and operating results as of and for the three and twelve months ended December 31, 2022 and 2021. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release of the Company, dated March 10, 2023](ea175011ex99-1_longeveron.htm) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| March 10, 2023 |  |  |
|  | **Longeveron Inc.** | **Longeveron Inc.** |
|  | By: | **/s/ James Clavijo** |
|  |  | James Clavijo<br> Chief Financial Officer |
|  |  | (principal executive officer) |

---

**Exhibit Index**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release of the Company, dated March 10, 2023](ea175011ex99-1_longeveron.htm) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) |

---

## Exhibit 99.1

**Exhibit 99.1**

**Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results**

*-- Full results from ELPIS I trial published in European Heart Journal Open –*

 

*-- First patient to be randomized in Japan Aging-Related Phase 2 study in Q1 –*

 

*-- Conference call scheduled for 8:30 a.m. ET today --*

 

**Miami, Florida –March 10, 2023—** Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for the fourth quarter and full year of 2022.

"Longeveron had a productive 2022, executing on multiple key milestones as we continued to advance Lomecel-B<sup>TM</sup> for multiple indications," said Wa'el Hashad, Chief Executive Officer. "Earlier this year, the full data from our ELPIS I trial of Lomecel-B<sup>TM</sup> for infants with HLHS was published in *European Heart Journal Open*. We are excited to continue advancing this opportunity through our ongoing Phase 2 ELPIS II trial. We have also made progress with our Japan Aging-Related Phase 2 study. We look forward to building on this progress through the rest of 2023."

**<u>Business Highlights and Anticipated Milestones:</u>**

**Lomecel-B<sup>TM</sup> for Hypoplastic Left Heart Syndrome (HLHS):**

● In January 2023, the full results of the ELPIS I Trial of Lomecel-B<sup>TM</sup> for hypoplastic left heart syndrome (HLHS) were published in *European Heart Journal Open*.

● Enrollment is ongoing in the ELPIS II trial, a 38-patient, randomized (1:1), blinded, controlled Phase 2 clinical trial intended to evaluate the safety and efficacy of intramyocardial injection of Lomecel-B<sup>TM</sup> in infants with HLHS who are undergoing Stage 2 surgery.

**Lomecel- B<sup>TM</sup> for Aging-Related Frailty:**

● The Company has initiated Phase 2 Clinical trial of Lomecel-B<sup>TM</sup> for Aging-Related Frailty in Japan. The Phase 2 Clinical trial is a 3-arm, parallel design, randomized (1:1:1), placebo-controlled, double-blind single infusion study of two different dose levels of Lomecel-B<sup>TM</sup>. The trial is expected to enroll 45 patients and has a primary objective of evaluating safety of Lomecel-B<sup>TM</sup> as a treatment for Aging-Related Frailty. The trial is being conducted in partnership with the National Center for Geriatrics & Gerontology (NCGG;Nagoya) and Juntendo University Hospital (Tokyo). We anticipate randomizing the first patient in this study before the end of the first quarter.

**Lomecel-B<sup>TM</sup> for Alzheimer's Disease:**

● In November, Longeveron completed enrollment in its Phase 2a trial of Lomecel-B<sup>TM</sup> for the treatment of Alzheimer's Disease (AD). The Phase 2a trial, called the CLEAR MIND trial, is a 48 patient, 4-arm, parallel design, randomized (1:1:1:1) clinical trial of Lomecel-B<sup>TM</sup> and is intended to evaluate the safety of a single and multiple infusion of two different dose levels compared to placebo in patients with mild AD. The primary endpoint is safety as measured by the occurrence of serious adverse events (SAEs) within the first 30 days after administration of Lomevel-B<sup>TM</sup>. The secondary and exploratory endpoints include brain volumetry by magnetic resonance imaging (MRI), biomarkers relevant to inflammation and endothelial/vascular systems, and measures of cognitive function.

● The Company expects to share topline results from CLEAR MIND in early 2024.

**Financial Results for Fourth Quarter and Full Year Ended December 31, 2022 and 2021**

**Revenue:** Revenue in the fourth quarter 2022 was $0.1 million compared to $0.2 million in the same period in 2021. The difference was primarily due to a decrease in clinical trial revenue during the fourth quarter 2022. During the fourth quarter 2022, fewer participants decided on having the treatment as compared to 2021.

Revenue for full year 2022 was $1.2 million compared to $1.3 million in 2021. Clinical trial revenue was $0.9 million for 2022 compared to $0.7 million for 2021, an increase of $0.2 million, or 29%. Participation increased in 2022 as compared to 2021 as the effects of travel restrictions due to Covid-19 decreased. Grant revenue was $0.3 million for 2022 compared to $0.6 million for 2021, a decrease of $0.3 million, or 53%, which was primarily due to a reduction in grant funds available due in part to the completion of some grant-funded clinical trials.

**R&D Expenses:** Research and development expenses in the fourth quarter of 2022 were $3.2 million compared to $1.7 million for the same period in 2021. The increase of $1.5 million, or 88%, was primarily due to an increase in research and development expenses related to the completion of clinical trials that were not reimbursable by grants. R&D Expenses for full year 2022 were $9.4 million compared to $7.1 million for 2021. The increase of $2.3 million, or 32% was primarily due to an increase in research and development expenses related to the completion of clinical trials that were not reimbursable by grants; The increase was offset by a decrease in equity-based compensation allocated to research and development expenses, which decreased from $2.2 million in 2021 to $1.1 million in 2022.

**G&A Expenses:** General and administrative expenses in the fourth quarter of 2022 were $1.6 million compared to $2.1 million for the same period in 2021. The decrease of approximately $0.5 million, or 24%, was primarily related to a decrease in equity based compensation expenses and professional fees. G&A Expenses for full year 2022 were $8.1 million compared to $9.7 million for 2021. The decrease of approximately $1.6 million, or 16%, was primarily related to a decrease of $3.0 million in equity-based compensation expenses allocated to general and administrative expenses. However, employee benefit expenses increased by $0.5 million, which included a $0.4 million increase in expenses related to employee recruitment and insurance and professional fees increased by $0.2 million.

**Selling & Marketing Expenses:** Selling and marketing expenses in the fourth quarter of 2022 and 2021 were $0.3 million. Selling and marketing expenses for full year 2022 were $1.0 million compared to $1.2 million for 2021. The decrease of $0.2 million, or 17%, was primarily due to a decrease in digital marketing expenses. Selling and marketing expenses consists primarily of investor and public relations expenses. Further and as disclosed in Note 13. Reclassification of Prior Year Presentations, on the Form 10-K, during 2021, $0.9 million in expenses related to investor and public relations was recorded as general and administrative expenses and was reclassified as selling and marketing expenses as they were in 2022.

**Net Loss:** Net loss was $4.5 million in the fourth quarter of 2022 compared to $4.1 million for the same period in 2021. Net loss for full year 2022 was $18.8 million compared to $17.0 million in 2021.

**Per Share:** Net loss per share was $0.21 in the fourth quarter of 2022 compared to $0.20 for the same period in 2021. Net loss per share for full year 2022 and 2021 was $0.90.

**Cash and Short Term Investments:** Cash and short-term investments was $19.6 million compared to $35.0 million as of December 31, 2022 and 2021, respectively. The decrease in cash period over period was the result of use of funds for operations. During 2021, we received gross proceeds from our initial public offering in February 2021 and our subsequent private placement offering in December 2021 of over $49.6 million.

**Financial Outlook**

Based on the Company's current operating plan and financial resources, we believe that our existing cash and short-term investments will be sufficient to cover expenses and capital requirements into first half of 2024.

**Conference Call and Webcast** 

Management will host a conference call today at 8:30 a.m. ET to discuss the Company's fourth quarter and full year 2022 financial results and provide a business update.

**Dial-in Number**

U.S. Dial-in Number: 833 470 1428

Canada Dial-in Number: 833 950 0062

Global Dial-In Numbers

Access code: 621807

U.S. Replay Dial-in Number: 866 813 9403

All Other Locations Dial-in Number: +44 204 525 0658

Access Code: 325814

An audio webcast of the call may also be accessed from the 'Investors' page of the Longeveron website at www.longeveron.com. A replay of the call will be available on the Longeveron website shortly after completion of the call.

**About Longeveron Inc.**

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company's lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently advancing Lomecel-B™ through clinical trials in three indications: hypoplastic left heart syndrome (HLHS), Alzheimer's Disease, and Aging-Related Frailty. Additional information about the Company is available at www.longeveron.com.

**Forward-Looking Statements**

Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management's current expectations, assumptions, and estimates of future performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as "believe," "expects," "may," "looks to," "will," "should," "plan," "intend," "on condition," "target," "see," "potential," "estimates," "preliminary," or "anticipates" or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements about the ability of Longeveron's clinical trials to demonstrate safety and efficacy of the Company's product candidates, and other positive results; the timing and focus of the Company's ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the Company's product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the Company's product candidates; the Company's ability to obtain and maintain regulatory approval of its product candidates; the Company's plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; existing regulations and regulatory developments in the U.S., Japan and other jurisdictions; the Company's plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the Company's ability to attract and retain such personnel; the Company's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company's need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the Company's financial performance, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditures requirements. Further information relating to factors that may impact the Company's results and forward-looking statements are disclosed in the Company's filings with the Securities and Exchange Commission, including Longeveron's Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 11, 2022, and the Company's Quarterly Reports on Form 10-Q. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

**Investor Contact:**

Stern IR, Inc.

212-698-8700

longeveron@sternir.com

Source: Longeveron Inc

**Longeveron Inc.**

**Selected Balance Sheet Data**

**(in thousands)**

---

| | | |
|:---|:---|:---|
|  | **December 31,<br> 2022** | **December 31,<br> 2021** |
| Cash | $10503 | $25658 |
| Short-term investments | 9155 | 9385 |
| Property and equipment | 2949 | 3062 |
| Intangible assets | 2409 | 2334 |
| Other assets | 2397 | 2327 |
| Total assets | $27413 | $42766 |
| Total liabilities | 6910 | 5313 |
| Total stockholders' equity | 20503 | 37453 |
| Total liabilities and stockholders' equity | $27413 | $42766 |

---

**Longeveron Inc.**

**Statements of Operations**

(In thousands, except per share data)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended<br> December 31** | **Three months ended<br> December 31** | **Year ended <br> December 31,** | **Year ended <br> December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
| **Revenues** |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Grant revenue | $41 | $44 | $282 | $598 |
| &nbsp;&nbsp;&nbsp; Clinical trial revenue | 80 | 165 | 940 | 708 |
| Total revenues | 121 | 209 | 1222 | 1306 |
| &nbsp;&nbsp;&nbsp; Cost of revenues | (175) | 140 | 725 | 716 |
| Gross profit | (54) | 69 | 497 | 590 |
| **Operating expenses** |  |  |  |  |
| &nbsp;&nbsp;&nbsp; General and administrative | 1637 | 2088 | 8119 | 9740 |
| &nbsp;&nbsp;&nbsp; Research and development | 3263 | 1734 | 9370 | 7092 |
| &nbsp;&nbsp;&nbsp; Selling and marketing | 285 | 279 | 1051 | 1214 |
| Total operating expenses | 5185 | 4101 | 18540 | 18046 |
| Loss from operations | (5239) | (4032) | (18043) | (17456) |
| **Other income and (expenses)** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Lawsuit expense |  |  | (1398) |  |
| &nbsp;&nbsp;&nbsp;Forgiveness of Paycheck Protection Program loan |  |  |  | 300 |
| &nbsp;&nbsp;&nbsp; Interest expense |  | (1) |  | (4) |
| &nbsp;&nbsp;&nbsp; Other refundable tax credits | 306 |  | 306 | 58 |
| &nbsp;&nbsp;&nbsp; Other (expense) income, net | 377 | (36) | 300 | 57 |
| Total other (expense) income, net | 783 | (37) | (792) | 411 |
| **Net loss** | $(4456) | $(4069) | $(18835) | $(17045) |
| **Basic and diluted net loss per share** | $(0.21) | $(0.20) | $(0.90) | $(0.90) |
| **Basic and diluted weighted average common shares outstanding** | 21017885 | 20019138 | 20969032 | 18915086 |

---

Source: Longeveron Inc.

Source: LGVN